Significant Improvement Shown in Prospective, Multicenter Study 3
*100% Responder rate for 1 point or more improvement in rTNSS; If using a 30% reduction in rTNSS from baseline, responder rate is 81%.
RhinAer fits seamlessly into the office or OR environment. Many payers have coverage policies in place for the treatment of nasal airway obstruction or chronic rhinitis. To learn more, contact Aerin Medical at (833)-484-8237
1 Data on file. Aerin Medical Quantitative Market Research.
2 van der Veen J, Seys SF, Timmermans M, Levie P, Jorissen M, Fokkens WJ, et al. Real-life study showing uncontrolled rhinosinusutus after sinus surgery in ateritary referral centre. Allergy. 2017;72(2):282-290.
3 RhinAer Stylus. Prospective, Non-randomized, Multi-Center Clinical Study. 50 patients. Endpoint from baseline to 52 weeks, Patient reported rTNSS score. Aerin Medical TR898.
4 100% Responder rate for 1 point or more improvement in rTNSS; If using a 30% reduction in rTNSS from baseline, responder rate is 81%. The patient who did not report at 52 weeks; reported as a responder at 26 weeks